Every 10-Q that INVO Fertility, Inc. (IVF) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow IVF and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IVF filings page.
INVO Fertility, Inc. reported higher clinic-driven revenue while remaining loss-making and disclosing substantial doubt about its ability to continue as a going concern. For the six months ended June 30, 2026, revenue was $4.19 million, up from $3.50 million in 2025, as the company expanded its fertility clinic footprint.
The company posted Q2 2026 net income of $888,740, driven largely by a $2.45 million gain on remeasurement of a note receivable and the step acquisition of its Alabama joint venture. However, for the six months it recorded a net loss of $4.65 million from continuing operations and used $3.02 million of cash in operating activities.
Cash increased to $3.73 million and total liabilities fell to $9.34 million from $13.00 million, while stockholders’ equity more than doubled to $16.49 million, helped by significant warrant exercises and preferred conversions. Management still expects to rely on additional debt or equity financing and warns that failure to raise capital could force delays, scaling back of growth plans, or potential cessation of operations.
INVO Fertility, Inc. reported first-quarter 2026 revenue of $2.0 million, up from $1.6 million a year earlier, driven mainly by clinic revenue. Despite this growth, the company posted a net loss from continuing operations of $5.5 million, compared with $1.5 million in the prior-year quarter, largely due to a $3.8 million non‑cash loss from changes in warrant fair value.
Cash rose to $4.9 million as of March 31 2026, from $2.1 million at year‑end 2025, helped by $7.1 million of warrant exercise proceeds. Total assets were $24.7 million and stockholders’ equity $15.0 million, while total liabilities fell to $9.6 million, aided by elimination of the warrant liability.
The company closed the acquisition of the Indiana Clinic on February 18 2026 for $760,000, including $360,000 in cash and $400,000 of new Series D preferred stock, expanding its U.S. fertility clinic footprint. However, management notes recurring losses, dependence on external financing, and substantial doubt about its ability to continue as a going concern without additional capital.
INVO Fertility, Inc. reports third‑quarter 2025 results with modest growth in fertility clinic activity but much larger losses after a strategic refocus. For the nine months ended September 30, 2025, total revenue rose to $5.26 million from $4.85 million, mainly from clinic revenue of $5.18 million. Operating expenses climbed to $11.08 million, and loss from operations widened to $5.83 million.
A major factor was the acquisition and subsequent divestiture of NAYA Therapeutics, which generated a $16.45 million loss from discontinued operations and contributed to a total net loss of $25.33 million for the period, versus $5.47 million a year earlier. Total assets fell to $18.83 million from $46.45 million after removing NAYA’s held‑for‑sale assets. Cash was $0.36 million, with $7.04 million used by operations and $6.69 million provided by financings, including equity and warrant proceeds.
The company ended the quarter with an accumulated deficit of $93.09 million and discloses that these losses, limited cash, and dependence on external financing raise substantial doubt about its ability to continue as a going concern.